ES2340400T3 - Celulas localizadas en tumores modificadas por ingenieria genetica para producir ligando inductor de apoptosis relacionado con el factor de necrosis tumoral (trail). - Google Patents

Celulas localizadas en tumores modificadas por ingenieria genetica para producir ligando inductor de apoptosis relacionado con el factor de necrosis tumoral (trail). Download PDF

Info

Publication number
ES2340400T3
ES2340400T3 ES05764208T ES05764208T ES2340400T3 ES 2340400 T3 ES2340400 T3 ES 2340400T3 ES 05764208 T ES05764208 T ES 05764208T ES 05764208 T ES05764208 T ES 05764208T ES 2340400 T3 ES2340400 T3 ES 2340400T3
Authority
ES
Spain
Prior art keywords
cells
trail
tumor
cell
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05764208T
Other languages
English (en)
Spanish (es)
Inventor
Alessandro M. Gianni
Carmelo Carlo-Stella
Francesco Colotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe SpA
Original Assignee
Dompe SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe SpA filed Critical Dompe SpA
Application granted granted Critical
Publication of ES2340400T3 publication Critical patent/ES2340400T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES05764208T 2004-07-29 2005-07-21 Celulas localizadas en tumores modificadas por ingenieria genetica para producir ligando inductor de apoptosis relacionado con el factor de necrosis tumoral (trail). Expired - Lifetime ES2340400T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017907 2004-07-29
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Publications (1)

Publication Number Publication Date
ES2340400T3 true ES2340400T3 (es) 2010-06-02

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05764208T Expired - Lifetime ES2340400T3 (es) 2004-07-29 2005-07-21 Celulas localizadas en tumores modificadas por ingenieria genetica para producir ligando inductor de apoptosis relacionado con el factor de necrosis tumoral (trail).

Country Status (24)

Country Link
US (1) US20070264231A1 (OSRAM)
EP (2) EP1621550A1 (OSRAM)
JP (1) JP5042826B2 (OSRAM)
KR (1) KR20070047757A (OSRAM)
CN (1) CN101076540B (OSRAM)
AT (1) ATE455847T1 (OSRAM)
AU (1) AU2005266543B2 (OSRAM)
BR (1) BRPI0513855A (OSRAM)
CA (1) CA2571426A1 (OSRAM)
DE (1) DE602005019050D1 (OSRAM)
DK (1) DK1771468T3 (OSRAM)
ES (1) ES2340400T3 (OSRAM)
HR (1) HRP20100227T1 (OSRAM)
IL (1) IL180233A (OSRAM)
MX (1) MX2007001152A (OSRAM)
NO (1) NO20070956L (OSRAM)
NZ (1) NZ552223A (OSRAM)
PL (1) PL1771468T3 (OSRAM)
PT (1) PT1771468E (OSRAM)
RS (1) RS51381B (OSRAM)
RU (1) RU2390558C2 (OSRAM)
SI (1) SI1771468T1 (OSRAM)
WO (1) WO2006010558A1 (OSRAM)
ZA (1) ZA200701231B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503468A (ja) * 2004-06-18 2008-02-07 ジェネンテック・インコーポレーテッド Ａｐｏ２ｌレセプターアゴニストおよびｎｋ細胞活性化因子の使用方法
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
WO2008142862A1 (ja) * 2007-05-18 2008-11-27 National University Corporation Asahikawa Medical College 血管内皮前駆細胞の移植による抗がん療法
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
CN104160027B (zh) * 2012-02-01 2016-06-22 浦项工科大学校产学协力团 同时表达十二聚体trail及hsv-tk自杀基因的载体及利用其的抗癌干细胞治疗剂
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
WO2016065330A1 (en) 2014-10-24 2016-04-28 Aladar Szalay Combination immunotherapy approach for treatment of cancer
CN116064401A (zh) * 2015-07-29 2023-05-05 昂克医疗有限公司 具有增强的细胞毒性的修饰的天然杀伤细胞和天然杀伤细胞系
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
CN113677791B (zh) * 2019-03-21 2024-12-03 昂克医疗有限公司 对细胞死亡具有增加的抗性的经修饰的免疫效应细胞
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
AU747602B2 (en) * 1997-06-04 2002-05-16 Oxford Biomedica (Uk) Limited Vector
WO2002022175A2 (en) * 2000-09-11 2002-03-21 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
EP1427813A2 (en) * 2000-10-24 2004-06-16 Immunex Corporation Method for dendritic cells-based immunotherapy of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
AU2005266543B2 (en) 2012-02-02
EP1771468B1 (en) 2010-01-20
EP1621550A1 (en) 2006-02-01
ZA200701231B (en) 2008-08-27
PL1771468T3 (pl) 2010-07-30
NZ552223A (en) 2009-01-31
RS51381B (sr) 2011-02-28
EP1771468A1 (en) 2007-04-11
PT1771468E (pt) 2010-04-20
ATE455847T1 (de) 2010-02-15
CA2571426A1 (en) 2006-02-02
HK1110874A1 (en) 2008-07-25
WO2006010558A1 (en) 2006-02-02
RU2007107369A (ru) 2008-09-10
WO2006010558A8 (en) 2006-08-24
JP2008507961A (ja) 2008-03-21
DK1771468T3 (da) 2010-05-25
KR20070047757A (ko) 2007-05-07
CN101076540B (zh) 2012-10-24
IL180233A0 (en) 2007-07-04
US20070264231A1 (en) 2007-11-15
CN101076540A (zh) 2007-11-21
HRP20100227T1 (hr) 2010-07-31
RU2390558C2 (ru) 2010-05-27
MX2007001152A (es) 2007-04-18
NO20070956L (no) 2007-02-20
AU2005266543A1 (en) 2006-02-02
DE602005019050D1 (de) 2010-03-11
BRPI0513855A (pt) 2008-05-20
SI1771468T1 (sl) 2010-07-30
JP5042826B2 (ja) 2012-10-03
IL180233A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
Redeker et al. Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination
ES2649967T3 (es) Inversión de los efectos del microentorno tumoral utilizando receptores quiméricos de citocinas
CN106519037B (zh) 可活化的嵌合受体
US20130071414A1 (en) Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
CN106659742A (zh) 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞
CN111743923B (zh) 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用
CN117304342B (zh) 嵌合抗原受体及其应用
AU2005266543B2 (en) Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
JP2019509715A (ja) 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
CN115838439A (zh) 嵌合转换受体基因修饰的nk细胞制备方法及应用
JP2015506697A (ja) １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
CN117511885B (zh) 提高识别和杀伤肿瘤能力的工程化til细胞及其应用
CN116041542A (zh) 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用
CN113416260B (zh) 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用
Grisendi et al. Tumor stroma manipulation by MSC
CN110106202A (zh) 抗肿瘤nk细胞的制备方法及其细胞与应用
KR102169798B1 (ko) 아데노바이러스의 감염 및 복제가 가능한 중간엽 줄기세포주
WO2025108160A9 (zh) 多功能基因修饰的免疫细胞及其制备方法和应用
KR20240050428A (ko) 키메라 항원 수용체(car) t 세포 요법 플랫폼
CN115806626A (zh) 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用
CN108218994A (zh) 一种方法培养t记忆干细胞
Qian et al. Gene therapy of cancer: induction of anti-tumor immunity
HK1110874B (en) Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)
WO2023276395A1 (ja) キメラサイトカイン受容体
HK40118403B (zh) 连续杀伤能力增强的工程化til细胞及其应用